Main Menu


Intercontinental is an international phase III randomised trial comparing intermittent versus continuous androgen suppression for patients with prostate-specific-antigen progression in the clinical absence of distant metastases following radiotherapy for prostate cancer.

Disease site: Urological  Prostate cancer

Treatment modality: Hormone therapy

Status: Closed

Trial details

The aim is to evaluate the use of intermittent androgen suppression (IAS) for overall survival, the potential for an improved quality of life during the non-treatment interval and decreased cost of therapy compared to continuous androgen ablation.

The trial is coordinated by the National Cancer Institute of Canada with ICR-CTSU responsible for UK centres. In the UK the trial is supported by the NCRI Prostate Clinical Studies Group.

The trial has recruited 1,386 patients internationally.

Chief Investigator: Professor David Dearnaley, The Royal Marsden NHS Foundation Trust

ICR-CTSU Scientific Lead: Dr Emma Hall

Trial management contact: Sarah Kernaghan - Clinical Trials Programme Manager, [email protected] 

ISRCTN: 22761545

Sponsor: The Institute of Cancer Research

Funding: Cancer Research UK (CRUKE/01/013)

Further information

Further information on the Intercontinental trial may be found on the following sites:

Patient friendly information on the Intercontinental trial at CancerHelp UK

Publications and presentations

Hall E, Patel S, Clarke N, Dearnaley D. A phase III randomized trial of post-radiotherapy intermittent androgen suppression (IAS) for prostate cancer patients with rising PSA-survey of interest. Clin. Oncol. (R. Coll. Radiol). 2002;14:S48 #D1.1

Clinical trials

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.